IR Portal for Exiqon
OMX Copenhagen: EXQ.CO
Seneste Kurs: 9,20
-1,08
Branche: Sundhed
RESSOURCER
14/10 2011ProInvestor Life Science Seminar 
8/9 2009Exiqon rings the NASDAQ Closing Bell, 8 September 2009
20/5 2009NIM Presentation 2009
8/9 2009Exiqon rings the NASDAQ Closing Bell, 8 September 2009
20/5 2009NIM Presentation 2009
Senest opdateret 24/2 2012
VIRKSOMHEDSBESKRIVELSE:
Exiqon operates in two business areas, Life Sciences and Diagnostics, which share:
• One vision - pursue new scientific discoveries to improve healthcare;
• One focus - the promise of miRNA as biological markers;
• One technology platform - our proprietary LNA™ (Locked Nucleic Acid) detection technology.
Exiqon’s Life Sciences business and its Diagnostics pipeline are helping to drive the development towards new diagnostic capabilities and personalized medicine by helping scientists to insightful understanding of the biological function of miRNA. Exiqon Diagnostics’ objective is to leverage the potential of miRNA as biological markers for novel diagnostic and prognostic products that can help physicians treating cancer make the most appropriate treatment decisions, increase the success rate of therapies and reduce the risk of adverse side effects and unnecessary costs.
Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information, visit www.exiqon.com.
• One vision - pursue new scientific discoveries to improve healthcare;
• One focus - the promise of miRNA as biological markers;
• One technology platform - our proprietary LNA™ (Locked Nucleic Acid) detection technology.
Exiqon’s Life Sciences business and its Diagnostics pipeline are helping to drive the development towards new diagnostic capabilities and personalized medicine by helping scientists to insightful understanding of the biological function of miRNA. Exiqon Diagnostics’ objective is to leverage the potential of miRNA as biological markers for novel diagnostic and prognostic products that can help physicians treating cancer make the most appropriate treatment decisions, increase the success rate of therapies and reduce the risk of adverse side effects and unnecessary costs.
Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information, visit www.exiqon.com.
INVESTOR RELATIONS KONTAKT
Chief Financial Officer
e-mail:
Senest opdateret 5/1 2010
FINANSIELLE TAL
| DKK’000 | 2011 | 2010 | 2009 |
|---|---|---|---|
| Revenue | 111.458 | 93.510 | 82.247 |
| Gross profit | 62.162 | 48.086 | 40.462 |
| Operating profit (EBIT) | -28.470 | -40.216 | -147.680 |
| Net profit / (loss), continuing operations | -24.894 | -42.115 | -146.596 |
| Net profit / (loss), discontinuing operations | 0.00 | -1.427 | -192.077 |
| Net profit/loss for the year | -24.894 | -43.542 | -338.818 |
| Cash and cash equivalents at period end | 12.151 | 18.184 | 45.496 |
| Cash flow from operations | -30.509 | -22.453 | -67.468 |
| Total assets | 122.501 | 129.397 | 175.311 |
| Shareholder equity | 80.158 | 84.667 | 121.600 |
| Total number of shares in thousands | 35.069.026 | 33.335 | 30.305 |
| EPS | -0,73 | -1,32 | -4,84 |
| BVPS | 4,20 | 2,54 | 4,01 |
| Average number of employees | 71 | 76 | 109 |
Senest opdateret 25/2 2011
Expect total revenue of around DKK 130 million
Forventet: 2012
Forventet: 2012
A positive EBIT
Forventet: 2012
Forventet: 2012
A positive cash flow from operations.
Forventet: 2012
Forventet: 2012
Senest opdateret 24/2 2012
Handelsbanken Capital Markets
Michael Novod
+45 33 41 82 00
Michael Novod
+45 33 41 82 00
Danske Equities
Martin Parkhøi
+45 33 44 04 41
Martin Parkhøi
+45 33 44 04 41
Senest opdateret 18/12 2009
Lars Kongsbak
CEO
Hans Henrik Chrois Christensen
CFO
Senest opdateret 18/12 2009
BEGIVENHEDER
Senest opdateret 25/5 2012
Senest opdateret 6/3 2012
Aktiekurs for Exiqon
Du skal opdatere din Flash Player for at se dette indhold
DINE MULIGHEDER
| Dit kursmål: ingen |
| Gennemsnitligt kursmål (AVG): 17,00 (1) |
| Hvor vil Exiqon lukke fra deres nuværende pris? Over  eller under  den nuværende kurs? |
|||
| Om en måned |
Om tre måneder |
Om seks måneder |
Om et år |
|
Brugernes anbefaling
SALG
KØB
|
|||
SKRIV INDLÆG
saving..